ANI Pharmaceuticals, Inc. (ANIP) Income Statement Analysis

See more : Jupiter Gold Corporation (JUPGF) Income Statement Analysis – Financial Results

Complete financial analysis of ANI Pharmaceuticals, Inc. (ANIP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ANI Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

ANI Pharmaceuticals, Inc. (ANIP)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.anipharmaceuticals.com

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998
Revenue	486.82M	316.39M	216.14M	208.48M	206.55M	201.58M	176.84M	128.62M	76.32M	55.97M	30.08M	2.30M	435.16K	2.47M	1.26M	3.78M	493.05K	14.44M	258.35K	77.89K	65.49K	2.83M	1.75M	2.00	1.00	123.06K
Cost of Revenue	181.51M	138.79M	100.61M	87.16M	63.15M	73.02M	79.03M	48.78M	12.69M	11.47M	9.97M	9.17M	50.00K	268.75K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-24.29K	0.00	0.00
Gross Profit	305.30M	177.60M	115.53M	121.32M	143.39M	128.55M	97.81M	79.84M	63.63M	44.50M	20.11M	-6.87M	385.16K	2.21M	1.26M	3.78M	493.05K	14.44M	258.35K	77.89K	65.49K	2.83M	1.75M	24.29K	1.00	123.06K
Gross Profit Ratio	62.71%	56.13%	53.45%	58.19%	69.42%	63.77%	55.31%	62.07%	83.37%	79.50%	66.84%	-298.44%	88.51%	89.14%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	1,214,600.00%	100.00%	100.00%
Research & Development	34.29M	22.32M	11.37M	16.00M	19.81M	15.39M	9.07M	2.91M	2.87M	2.68M	1.71M	16.89M	44.18M	39.71M	13.68M	15.79M	4.75M	3.86M	6.41M	9.16M	3.69M	4.79M	2.14M	1.89M	660.59K	1.40M
General & Administrative	0.00	0.00	0.00	0.00	0.00	44.06M	31.58M	27.83M	21.16M	17.94M	16.39M	8.23M	6.98M	5.94M	5.67M	5.96M	4.33M	7.03M	3.05M	3.08M	2.33M	1.77M	2.30M	1.68M	853.39K	1.11M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	161.70M	124.04M	84.29M	64.99M	55.84M	44.06M	31.58M	27.83M	21.16M	17.94M	16.39M	8.23M	6.98M	5.94M	5.67M	5.96M	4.33M	7.03M	3.05M	3.08M	2.33M	1.77M	2.30M	1.68M	853.39K	1.11M
Other Expenses	62.35M	56.97M	48.03M	55.90M	51.32M	-550.00K	55.00K	-74.00K	41.00K	160.00K	-305.00K	353.95K	148.24K	167.99K	20.33M	43.14K	89.82K	117.78K	100.94K	101.94K	92.93K	92.10K	92.56K	122.79K	90.97K	269.70K
Operating Expenses	258.33M	203.33M	143.70M	136.89M	126.97M	93.19M	68.58M	53.08M	30.93M	24.49M	19.21M	25.47M	51.31M	45.81M	39.68M	21.79M	9.17M	11.00M	9.56M	12.34M	6.11M	6.64M	4.53M	3.69M	1.60M	2.78M
Cost & Expenses	439.85M	342.12M	244.31M	224.05M	190.12M	166.22M	147.61M	101.86M	43.62M	35.96M	29.18M	25.47M	51.36M	46.08M	39.68M	21.79M	9.17M	11.00M	9.56M	12.34M	6.11M	6.64M	4.53M	3.66M	1.60M	2.78M
Interest Income	0.00	28.05M	11.92M	9.45M	12.97M	0.00	0.00	0.00	0.00	0.00	0.00	8.54K	8.33K	12.67K	11.65K	588.46K	1.10M	428.34K	401.19K	250.42K	86.59K	63.79K	174.42K	227.72K	0.00	0.00
Interest Expense	26.94M	28.05M	11.92M	9.45M	12.97M	14.76M	12.04M	11.33M	11.01M	787.00K	467.00K	348.02K	681.57K	688.08K	147.03K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	59.79M	56.97M	47.25M	44.64M	44.61M	33.74M	27.93M	22.34M	6.90M	3.88M	1.11M	258.95K	148.24K	167.99K	137.28K	43.14K	89.82K	117.78K	100.94K	101.94K	92.93K	92.10K	110.56K	122.79K	90.97K	139.77K
EBITDA	106.60M	48.07M	-1.68M	29.07M	60.74M	69.10M	57.16M	56.31M	39.64M	24.04M	7.51M	-27.23M	-50.78M	-45.34M	-47.24M	-17.38M	-7.49M	3.56M	-9.55M	-11.91M	-5.95M	-3.72M	-2.68M	-3.31M	-1.51M	-2.52M
EBITDA Ratio	21.90%	10.09%	6.82%	13.71%	29.44%	34.01%	32.35%	38.12%	51.94%	42.96%	5.66%	-995.51%	-11,667.01%	-1,678.41%	-2,330.70%	-475.31%	-1,742.13%	32.10%	-3,271.24%	-15,618.58%	-9,089.41%	-131.22%	-153.10%	-177,106,050.00%	-151,397,600.00%	-2,047.48%
Operating Income	46.97M	-25.06M	-32.51M	-16.06M	16.35M	35.36M	28.33M	20.08M	32.70M	20.01M	898.00K	-23.17M	-50.93M	-43.61M	-38.43M	-18.01M	-8.68M	3.44M	-9.30M	-12.27M	-6.05M	-3.81M	-2.79M	-3.66M	-1.60M	-2.66M
Operating Income Ratio	9.65%	-7.92%	-15.04%	-7.71%	7.92%	17.54%	16.02%	15.61%	42.84%	35.74%	2.99%	-1,007.14%	-11,703.01%	-1,762.50%	-3,054.36%	-476.45%	-1,760.34%	23.82%	-3,600.61%	-15,749.47%	-9,231.29%	-134.47%	-159.43%	-183,245,550.00%	-160,494,100.00%	-2,161.05%
Total Other Income/Expenses	-27.10M	-27.38M	-16.27M	-9.95M	-13.19M	-15.31M	-11.98M	-11.40M	-10.97M	-627.00K	-772.00K	-5.60M	-681.67K	-2.59M	-9.10M	-17.41B	-7.58B	-1.08M	-348.81K	250.42K	86.59K	0.00	174.42K	0.00	0.00	0.00
Income Before Tax	19.87M	-62.67M	-56.06M	-25.96M	3.16M	20.05M	16.35M	8.68M	21.73M	19.38M	126.00K	-27.84M	-51.61B	-46.20B	-47.53B	-17.43B	-7.58B	2.79B	-9.65B	-12.02M	-5.96M	-3.81M	-2.61M	0.00	0.00	0.00
Income Before Tax Ratio	4.08%	-19.81%	-25.94%	-12.45%	1.53%	9.95%	9.24%	6.75%	28.48%	34.62%	0.42%	-1,210.03%	-11,859,661.73%	-1,867,089.37%	-3,777,879.80%	-460,882.47%	-1,538,256.46%	19,331.99%	-3,735,629.43%	-15,427.94%	-9,099.08%	-134.47%	-149.44%	0.00%	0.00%	0.00%
Income Tax Expense	1.09M	-14.77M	-13.46M	-3.41M	-2.94M	4.56M	17.43M	4.74M	6.36M	-9.37M	20.00K	-121.79K	681.67K	2.59M	9.10M	-17.41B	-7.58B	648.49K	348.81K	0.00	0.00	0.00	0.00	-227.72K	-198.68K	0.00
Net Income	18.78M	-47.90M	-42.60M	-22.55M	6.09M	15.49M	-1.08M	3.93M	15.38M	28.75M	301.00K	-27.72M	-51.61M	-46.20M	-47.53M	-17.43M	-7.58M	2.79M	-9.65M	-12.02M	-5.96M	-3.81M	-2.61M	-3.44M	-1.41M	-2.66M
Net Income Ratio	3.86%	-15.14%	-19.71%	-10.82%	2.95%	7.69%	-0.61%	3.06%	20.14%	51.36%	1.00%	-1,204.73%	-11,859.66%	-1,867.09%	-3,777.88%	-460.88%	-1,538.26%	19.33%	-3,735.63%	-15,427.94%	-9,099.08%	-134.47%	-149.44%	-171,859,750.00%	-140,625,900.00%	-2,161.05%
EPS	0.95	-2.95	-3.38	-1.88	0.51	1.33	-0.09	0.34	1.34	2.61	-0.92	-7.64	-18.88	-25.23	-50.39	-22.97	-10.71	4.68	-17.92	-25.23	-19.44	-18.28	-14.50	-21.51	-10.24	-27.47
EPS Diluted	0.94	-2.95	-3.38	-1.88	0.50	1.32	-0.09	0.34	1.32	2.59	-0.92	-7.64	-18.88	-25.23	-50.39	-22.97	-10.71	4.68	-17.92	-25.23	-19.44	-18.28	-14.50	-21.51	-10.24	-27.47
Weighted Avg Shares Out	18.00M	16.26M	12.60M	11.96M	11.84M	11.68M	11.55M	11.45M	11.37M	10.94M	5.07M	3.63M	2.73M	1.83M	943.11K	758.54K	707.93K	588.64K	538.67K	476.26K	306.63K	208.42K	180.15K	159.82K	137.29K	96.83K
Weighted Avg Shares Out (Dil)	18.19M	16.26M	12.60M	11.96M	12.04M	11.77M	11.55M	11.57M	11.56M	11.05M	5.07M	3.63M	2.73M	1.83M	943.11K	758.54K	707.93K	596.78K	538.67K	476.26K	306.63K	208.42K	180.15K	159.82K	137.29K	96.83K

ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance

May 10, 2024globenewswire.com

BAUDETTE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the three months ended March 31, 2024.

Why Earnings Season Could Be Great for ANI Pharmaceuticals (ANIP)

May 9, 2024zacks.com

ANI Pharmaceuticals (ANIP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?

May 6, 2024zacks.com

ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

May 3, 2024zacks.com

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences

May 1, 2024globenewswire.com

BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New...

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET

April 18, 2024globenewswire.com

BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open.

Why ANI (ANIP) is Poised to Beat Earnings Estimates Again

April 15, 2024zacks.com

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension

April 9, 2024globenewswire.com

BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®.

Wall Street Analysts Think ANI (ANIP) Is a Good Investment: Is It?

April 5, 2024zacks.com

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do...